Skip to main content
Top
Published in: Familial Cancer 2/2014

01-06-2014 | Original Article

Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme

Authors: D. Gareth R. Evans, Sarah Ingham, Sarah Dawe, L. Roberts, F. Lalloo, A. R. Brentnall, P. Stavrinos, Anthony Howell

Published in: Familial Cancer | Issue 2/2014

Login to get access

Abstract

Accurate individualized breast cancer risk assessment is essential to provide risk–benefit analysis prior to initiating interventions designed to lower breast cancer risk and start surveillance. We have previously shown that a manual adaptation of Claus tables was as accurate as the Tyrer–Cuzick model and more accurate at predicting breast cancer than the Gail, Claus model and Ford models. Here we reassess the manual model with longer follow up and higher numbers of cancers. Calibration of the manual model was assessed using data from 8,824 women attending the family history evaluation and screening programme in Manchester UK, with a mean follow up of 9.71 years. After exclusion of 40 prevalent cancers, 406 incident breast cancers occurred, and 385.1 were predicted (O/E = 1.05, 95 % CI 0.95–1.16) using the manual model. Predictions were close to that of observed cancers in all risk categories and in all age groups, including women in their forties (O/E = 0.99, 95 % CI 0.83–1.16). Manual risk prediction with use of adjusted Claus tables and curves with modest adjustment for hormonal and reproductive factors was a well-calibrated approach to breast cancer risk estimation in a UK family history clinic.
Literature
1.
go back to reference Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early onset breast cancer: implications for risk prediction. Cancer 73:643–651PubMedCrossRef Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early onset breast cancer: implications for risk prediction. Cancer 73:643–651PubMedCrossRef
2.
go back to reference Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829–1846PubMedCrossRef Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829–1846PubMedCrossRef
3.
go back to reference Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77(11):2318–2324PubMedCrossRef Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77(11):2318–2324PubMedCrossRef
4.
go back to reference Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689PubMedCentralPubMedCrossRef Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689PubMedCentralPubMedCrossRef
5.
go back to reference Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158PubMedCentralPubMedCrossRef Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158PubMedCentralPubMedCrossRef
7.
go back to reference Tyrer JP, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111–1130PubMedCrossRef Tyrer JP, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111–1130PubMedCrossRef
8.
go back to reference Cuzick J, Howell A, Powles T, Forbes J, Baum M (2002) First results from the International breast cancer intervention study (IBIS-I): a randomised prevention trial. Lancet 360:817–824PubMedCrossRef Cuzick J, Howell A, Powles T, Forbes J, Baum M (2002) First results from the International breast cancer intervention study (IBIS-I): a randomised prevention trial. Lancet 360:817–824PubMedCrossRef
9.
go back to reference Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40(11):807–814PubMedCentralPubMedCrossRef Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40(11):807–814PubMedCentralPubMedCrossRef
11.
go back to reference Evans DGR, Fentiman IS, McPherson K, Asbury D, Ponder BAJ, Howell A (1994) Familial breast cancer. British Med J 308:183–187CrossRef Evans DGR, Fentiman IS, McPherson K, Asbury D, Ponder BAJ, Howell A (1994) Familial breast cancer. British Med J 308:183–187CrossRef
13.
go back to reference Lalloo F, Kerr B, Friedman J, Evans DGR (2005) Risk estimation for breast cancer. In: Evans DGR, Kerr B, Lalloo F, Friedman J (eds) Risk assessment and management in cancer genetics. Oxford University Press, Oxford, pp 47–64 Lalloo F, Kerr B, Friedman J, Evans DGR (2005) Risk estimation for breast cancer. In: Evans DGR, Kerr B, Lalloo F, Friedman J (eds) Risk assessment and management in cancer genetics. Oxford University Press, Oxford, pp 47–64
14.
go back to reference Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER (2008) Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting. BMC Cancer 8(1):155PubMedCentralPubMedCrossRef Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER (2008) Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting. BMC Cancer 8(1):155PubMedCentralPubMedCrossRef
15.
go back to reference McIntosh A, Shaw C, Evans G, Turnbull N, Bahar N, Barclay M, Easton D, Emery J, Gray J, Halpin J, Hopwood P, McKay J, Sheppard C, Sibbering M, Watson W, Wailoo A, Hutchinson A (2004 updated 2006) Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. National Collaborating Centre for Primary Care/University of Sheffield, London. NICE guideline CG041. www.nice.org.uk McIntosh A, Shaw C, Evans G, Turnbull N, Bahar N, Barclay M, Easton D, Emery J, Gray J, Halpin J, Hopwood P, McKay J, Sheppard C, Sibbering M, Watson W, Wailoo A, Hutchinson A (2004 updated 2006) Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. National Collaborating Centre for Primary Care/University of Sheffield, London. NICE guideline CG041. www.​nice.​org.​uk
16.
go back to reference Breslow NE, Day NE (1987) Statistical methods in cancer research Vol II. The design and analysis of cohort studies (IARC) Scientific Publication No 82. International Agency for Research on Cancer, Lyon Breslow NE, Day NE (1987) Statistical methods in cancer research Vol II. The design and analysis of cohort studies (IARC) Scientific Publication No 82. International Agency for Research on Cancer, Lyon
17.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. Lancet 358:1389–1399CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. Lancet 358:1389–1399CrossRef
19.
go back to reference Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, Easton DF (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98(12):2015CrossRef Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, Easton DF (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98(12):2015CrossRef
20.
go back to reference Norman RP, Evans DG, Easton DF, Young KC (2007) The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49. Eur J Health Econ 8(2):137–144PubMedCrossRef Norman RP, Evans DG, Easton DF, Young KC (2007) The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49. Eur J Health Econ 8(2):137–144PubMedCrossRef
21.
go back to reference Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA, American Cancer Society Breast Cancer Advisory Group (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89PubMedCrossRef Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA, American Cancer Society Breast Cancer Advisory Group (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89PubMedCrossRef
22.
go back to reference Evans DGR, Lennard F, Pointon LJ, Ramus SJ, Gayther SA, Sodha N, Kwan-Lim GE, Leach MO, Warren R, Thompson D, Easton DF, Eeles R, On behalf of The UK study of MRI screening for breast cancer in women at high risk (MARIBS) (2009) Eligibility for MRI screening in the UK: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS study. Cancer Epid Biomarkers Prev 18(7):2123–2131CrossRef Evans DGR, Lennard F, Pointon LJ, Ramus SJ, Gayther SA, Sodha N, Kwan-Lim GE, Leach MO, Warren R, Thompson D, Easton DF, Eeles R, On behalf of The UK study of MRI screening for breast cancer in women at high risk (MARIBS) (2009) Eligibility for MRI screening in the UK: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS study. Cancer Epid Biomarkers Prev 18(7):2123–2131CrossRef
23.
go back to reference Ozanne EM, Drohan B, Bosinoff P, Semine A, Jellinek M, Cronin C, Millham F, Dowd D, Rourke T, Block C, Hughes KS (2013) Which risk model to use? Clinical implications of the ACS MRI screening guidelines. Cancer Epidemiol Biomarkers Prev 22(1):146–149PubMedCrossRef Ozanne EM, Drohan B, Bosinoff P, Semine A, Jellinek M, Cronin C, Millham F, Dowd D, Rourke T, Block C, Hughes KS (2013) Which risk model to use? Clinical implications of the ACS MRI screening guidelines. Cancer Epidemiol Biomarkers Prev 22(1):146–149PubMedCrossRef
24.
go back to reference Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ (2009) Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat 115(2):381–390PubMedCrossRef Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ (2009) Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat 115(2):381–390PubMedCrossRef
25.
go back to reference Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB (2012) Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res 14(6):R144PubMedCrossRef Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB (2012) Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res 14(6):R144PubMedCrossRef
26.
go back to reference van Asperen CJ, Jonker MA, Jacobi CE, van Diemen-Homan JE, Bakker E, Breuning MH, van Houwelingen JC, de Bock GH (2004) Risk estimation for healthy women from breast cancer families: new insights and new strategies. Cancer Epidemiol Biomarkers Prev 13(1):87–93PubMedCrossRef van Asperen CJ, Jonker MA, Jacobi CE, van Diemen-Homan JE, Bakker E, Breuning MH, van Houwelingen JC, de Bock GH (2004) Risk estimation for healthy women from breast cancer families: new insights and new strategies. Cancer Epidemiol Biomarkers Prev 13(1):87–93PubMedCrossRef
Metadata
Title
Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme
Authors
D. Gareth R. Evans
Sarah Ingham
Sarah Dawe
L. Roberts
F. Lalloo
A. R. Brentnall
P. Stavrinos
Anthony Howell
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2014
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-013-9694-z

Other articles of this Issue 2/2014

Familial Cancer 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine